Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
VSTM 
Verastem Inc (VSTM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: VSTM (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $15.5
1 Year Target Price $15.5
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -70.28% | Avg. Invested days 33 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 572.07M USD | Price to earnings Ratio - | 1Y Target Price 15.5 |
Price to earnings Ratio - | 1Y Target Price 15.5 | ||
Volume (30-day avg) 9 | Beta 0.89 | 52 Weeks Range 2.54 - 11.25 | Updated Date 10/14/2025 |
52 Weeks Range 2.54 - 11.25 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.39 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2047.92% |
Management Effectiveness
Return on Assets (TTM) -64.8% | Return on Equity (TTM) -437.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 473684977 | Price to Sales(TTM) 267.7 |
Enterprise Value 473684977 | Price to Sales(TTM) 267.7 | ||
Enterprise Value to Revenue 221.66 | Enterprise Value to EBITDA -0.19 | Shares Outstanding 61545270 | Shares Floating 45878306 |
Shares Outstanding 61545270 | Shares Floating 45878306 | ||
Percent Insiders 0.82 | Percent Institutions 89.08 |
Upturn AI SWOT
Verastem Inc
Company Overview
History and Background
Verastem, Inc. is a biopharmaceutical company dedicated to discovering and developing new medicines to improve the lives of patients with cancer. Founded in 2010, the company focuses on developing therapies that target cancer stem cells.
Core Business Areas
- Oncology Drug Development: Focused on discovering and developing drugs targeting cancer stem cells to treat various cancers.
Leadership and Structure
The leadership team consists of the CEO, CFO, CSO, and other key executives. The organizational structure includes research and development, clinical development, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- Mafotersen: An antisense oligonucleotide targeting the mRNA of KRAS-G12D. Mafotersen is being developed for KRAS-G12D mutant non-small cell lung cancer. It is currently in development stages; therefore, no market share or revenue data is available. Competitors include companies developing KRAS inhibitors and other lung cancer therapies.
- Avutometinib (VS-6766): A RAF/MEK clamp. Currently being investigated in multiple oncology settings. It is in clinical trials, so there is currently no market share or revenue data available. Competitors include companies developing MEK inhibitors such as Novartis, Roche, and AstraZeneca.
Market Dynamics
Industry Overview
The oncology drug market is a large and rapidly growing market driven by an aging population, increasing cancer incidence, and advances in cancer treatment. The market includes targeted therapies, immunotherapies, chemotherapies, and supportive care medications.
Positioning
Verastem Inc. focuses on developing innovative therapies targeting specific cancer mutations. Their position lies in precision medicine and targeting difficult-to-treat cancers.
Total Addressable Market (TAM)
The global oncology market is estimated to reach over $300 billion in the coming years. Verastem Inc. is positioned to capture a segment of this market by developing targeted therapies.
Upturn SWOT Analysis
Strengths
- Novel approach targeting cancer stem cells
- Strong intellectual property portfolio
- Experienced management team
- Targeted therapies addressing unmet medical needs
Weaknesses
- Limited product portfolio
- Dependence on clinical trial results
- High R&D expenses
- No current FDA approved drugs to generate revenue
Opportunities
- Expansion of pipeline through strategic partnerships
- Potential for breakthrough therapies in oncology
- Increasing demand for personalized medicine
- Advancements in cancer diagnostics
Threats
- Regulatory hurdles and approval delays
- Competition from established pharmaceutical companies
- Patent expiration and generic entry
- Unsuccessful clinical trial results
Competitors and Market Share
Key Competitors
- MRTX
- AMGN
- GILD
Competitive Landscape
Verastem Inc. faces competition from larger pharmaceutical companies with more resources and established pipelines. However, Verastem's targeted approach could give it a competitive advantage in certain niches.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on successful clinical trials and achieving milestones.
Future Projections: Future projections depend on analyst estimates of drug approval and sales.
Recent Initiatives: Recent initiatives include advancing clinical trials, seeking partnerships, and expanding the pipeline.
Summary
Verastem Inc. is a biopharmaceutical company with a promising approach to cancer treatment through its focus on cancer stem cells. However, the company faces significant risks associated with drug development, regulatory hurdles, and competition. Successful clinical trial results and strategic partnerships are crucial for the company's future success. Currently, the company does not generate revenue as it is pre-commercialization and generates losses.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Verastem Inc. SEC Filings
- Company Website
- Analyst Reports
- Industry Databases
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Verastem Inc
Exchange NASDAQ | Headquaters Needham, MA, United States | ||
IPO Launch date 2012-01-27 | President, CEO & Director Mr. Daniel W. Paterson | ||
Sector Healthcare | Industry Biotechnology | Full time employees 78 | Website https://www.verastem.com |
Full time employees 78 | Website https://www.verastem.com | ||
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.